Preoxygenation With Optiflow™ - the Effect of Speech on Lung Oxygenation.
- Conditions
- Unrecognized Condition
- Interventions
- Device: Optiflow
- Registration Number
- NCT03766646
- Brief Summary
If a patient speaks during the process of preoxygenation with high-flow nasal oxygen via the Optiflow™ system, is the efficacy reduced as measured by end-tidal lung oxygen content?
- Detailed Description
This is a randomised controlled trial on 34 patients undergoing routine elective surgery at the Princess Anne Hospital, Southampton. The study will take place from September 2018 to January 2019 and involve preoxygenating all participants for three minutes using the Optiflow™ device. During this time, participants will be instructed to either read aloud a standardised text or to breathe through their nose with a closed mouth. At the end of 3 minutes, the primary outcome, ETO2, will be measured and recorded.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Female
- Target Recruitment
- 34
- BMI 18-35, ASA category 1 or 2
- Inability to read/ follow instructions, Heavily sedated
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Non-speech Optiflow Participants were asked to breathe in and out of their nose for 3 minutes, with a closed mouth, whilst receiving oxygen from the Optiflow device. At the end of 3 minutes End Tidal Oxygen was measured and recorded. Speech Optiflow Participants were asked to read a standardised script aloud for 3 minutes whilst receiving oxygen from the Optiflow device. At the end of 3 minutes End Tidal Oxygen was measured and recorded.
- Primary Outcome Measures
Name Time Method End Tidal Oxygen Fraction At the end of 3 minutes preoxygenation Oxygen fraction in first expired breath post preoxygenation
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
University Hospital Southampton
🇬🇧Southampton, Hants, United Kingdom